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cancer patients generally report greater well-being across all
domains, but age-adjusted results suggest hepatobiliary and
head/neck cancer have signiﬁcantly worse HRQL among differ-
ent types of cancer, particularly in terms of PWB and FWB.
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OBJECTIVES: To evaluate brain cancer speciﬁc health related
quality-of-life (HRQOL) instruments used in glioblastoma mul-
tiforme (GBM) patients for group and individual level decision-
making. METHODS: An extensive literature search was
conducted to identify brain cancer speciﬁc HRQOL instruments
using several databases including Medline, PsycINFO, and
Health and Psychosocial Instruments. Key search terms included
“quality of life” and “glioblastoma”. Only brain cancer speciﬁc
HRQOL instruments evaluating GBM patients were retained for
evaluation of item information, practicality, breadth, depth, reli-
ability (group level based on Nunnally & Bernstein 1994 and
individual level based on McHorney & Tarlov 1995 criteria),
validity and responsiveness. RESULTS: Four instruments were
identiﬁed: extended Rotterdam Symptom Checklist (e-RSCL);
European Organization for Research and Treatment of Cancer
quality-of-life core 30 (EORTC QLQ C30) with brain cancer
module (BCM20); EORTC QLQ C30+3 with BCM20; and a
newly developed instrument deriving its core from the Sickness
Impact Proﬁle (SIP) with addition of a brain cancer module (BC).
The EORTC QLQ C30 was the most widely used instrument
and satisﬁed practicality, breadth and validity criteria (conver-
gent: r = 0.61–0.70, p < 0.05; known-groups: p < 0.05). This
instrument offered the most extensive reliability information
with 4 of 9 domains meeting the 0.70 criterion for group level
decision-making. The SIP core with BC was notable for high
levels of missing psychometric data. CONCLUSION: Measuring
the impact of treatment on HRQOL is critical, especially in ter-
minal conditions. However, none of the instruments in this study
met the criteria for individual level decision-making. This was
due in part to unavailable psychometric data as well as data not
meeting study criteria. Based on the results from this study, the
EORTC QLQ C30 is recommended for use in group level deci-
sion-making in conjunction with another HRQOL instrument,
for example a generic instrument. Further studies are required to
evaluate the psychometric properties of the BCM20.
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OBJECTIVES: To assess health-related quality of life (HRQOL)
in patients with metastatic renal cell carcinoma (mRCC) treated
with axitinib (AG-013736), a potent vascular endothelial growth
factor receptor inhibitor. METHODS: In a single-arm phase II
trial, mRCC patients who had received one prior cytokine-based
therapy were treated with axitinib 5 mg orally BID until disease
progression or no response (46% of patients had a PR, and 40%
had stable disease). HRQOL, a secondary endpoint, was mea-
sured using the European Organization for the Research and
Treatment of Cancer Quality of Life Questionnaire-Core 30
(EORTC-QLQ-C30). The QLQ-C30 consists of 30 questions,
rated on a 0–4 scale, measuring functional status, symptoms, and
global health. Higher scores on the functional status and global
health scales reﬂect better HRQOL, whereas higher scores on the
symptom scales indicate more severe symptoms. QLQ-C30 was
completed at baseline, monthly for the ﬁrst two cycles, every 2
cycles thereafter, and at follow-up. Longitudinal analyses were
used to evaluate HRQOL data through 36 cycles of treatment.
RESULTS: Fifty-four patients completed baseline HRQOL
assessments. Statistically signiﬁcant changes (P < 0.05) were
observed in average scores from baseline to post-treatment in the
role, cognitive and social functioning scales, and the nausea/vom-
iting, pain and diarrhea symptoms. These changes were approx-
imately <1/4 of a response category. The exception was diarrhea,
with a 1/2 category change, which equated to a change from
“no” to “a little” diarrhea. CONCLUSION: Although some
measures of functioning and symptoms are statistically signiﬁ-
cant, interpretation of QLQ-C30 scores from the current litera-
ture (King 1996 Qual Life Res; Osoba 1998 JCO) indicate that
changes observed in the study are, overall, too small to reﬂect a
palpable change in patient functioning and symptoms. Thus,
treatment with axitinib demonstrated minimal disruptions in
HRQOL compared to baseline levels in mRCC patients.
PCN55
TRANSLATION AND CULTURAL ADAPTATION OF HEALTH
UTILITIES INDEX (HUI) FOR ASSESSING EFFECTS OF
NEUTROPENIA AMONG PEDIATRIC ONCOLOGY PATIENTS
IN TURKEY
Horsman JR1, Boran P2,Tokuc G2, Furlong W3, Uygur P2,Vagas E2
1McMaster University, Hamilton, ON, Canada, 2Dr. Lutﬁ Kirdar Kartal
Research and Training Hospital, Istanbul,Turkey, 3Health Utilities Inc
(HUInc), Dundas, ON, Canada
OBJECTIVES: HUI is a family of multi-attribute, health-status
classiﬁcation and preference scoring systems for general popula-
tion health surveys and clinical research studies including cost-
utility economic evaluations of alternative treatments. It has been
translated and culturally adapted into many languages. This is
the ﬁrst report of HUI in Turkish. METHODS: The original
English-language health-status classiﬁcation system was trans-
lated into Turkish by 3 physicians from the pediatric oncology
clinic in Istanbul. The consensus forward translation was inde-
pendently back translated and then reviewed by HUInc staff. It
provides the keywords for subsequent HUI questionnaire trans-
lation. The same forward/backward translation strategy with 
all-party consensus produced the interviewer-administered 
questionnaire for proxy assessments (HUI23P1Tr.40Q). The
questionnaire was evaluated for acceptability and construct
validity by interviewing parents of patients who developed neu-
tropenia during their ﬁrst chemotherapy cycle. Parents were
interviewed twice at the Istanbul clinic, during and again after
the neutropenic episode. Upon completion of the ﬁrst interview,
parents were asked informally about the questionnaire readabil-
ity and suitability. Utility scores are from the original published
functions based on general population preference measurements
and differences in mean utility scores were tested using ANOVA.
RESULTS: Parents of 50 newly diagnosed patients (26 males,
mean age 91.3 months) were interviewed. The questionnaire was
reported by all parents to be understandable and acceptable.
Overall utility scores of health-related quality of life (HRQL)
during neutropenic episodes (HUI2 mean = 0.65, SD = 0.251;
HUI3 mean = 0.60, SD = 0.328) were signiﬁcantly and impor-
tantly lower (HUI2 p = 0.008, HUI3 p = 0.034) than after recov-
ery (HUI2 mean = 0.79, SD = 0.244; HUI3 mean = 0.75, SD =
0.315) as were the single-attribute scores for HUI2 and HUI3
